490 related articles for article (PubMed ID: 31707713)
1. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
3. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
4. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
5. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
7. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
Brenner DM; Sayuk GS; Abel JL; Burslem K
J Manag Care Spec Pharm; 2021 Apr; 27(4):469-477. PubMed ID: 33769858
[No Abstract] [Full Text] [Related]
8. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
9. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
10. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Keating GM
Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
[TBL] [Abstract][Full Text] [Related]
11. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
[TBL] [Abstract][Full Text] [Related]
12. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
[TBL] [Abstract][Full Text] [Related]
13. New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
[TBL] [Abstract][Full Text] [Related]
14. Dietary and pharmacological treatment of abdominal pain in IBS.
Camilleri M; Boeckxstaens G
Gut; 2017 May; 66(5):966-974. PubMed ID: 28232472
[TBL] [Abstract][Full Text] [Related]
15. Modern Management of Irritable Bowel Syndrome: More Than Motility.
Tack J; Vanuytsel T; Corsetti M
Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
18. Eluxadoline: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
[TBL] [Abstract][Full Text] [Related]
19. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
[TBL] [Abstract][Full Text] [Related]
20. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
